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ABSTRACT
Although new heptatis C virus treatments have increased efficacy and improved safety profiles, they also come
with risk. We describe a 66-year-old white man with Child-Pugh A cirrhosis secondary to heptatis C virus geno-
type 3, who suffered from an acute kidney injury after treatment with sofosbuvir and daclatasvir. Kidney biopsy
demonstrated evidence of acute tubular interstitial nephritis consistent with a drug reaction. A trial of steroid
therapy was effective, and his creatinine continues to improve significantly. Our case is the first report in the lit-
erature that highlights potentially serious interstitial nephritis associated with sofosbuvir and daclatasvir use.
INTRODUCTION
Acute interstitial nephritis (AIN) is a frequent cause of acute kidney failure, occurring in 15–27% of renal biopsies
performed for this indication.1 This under-reported condition is frequently clinically diagnosed by noting improve-
ment in renal function after cessation of possible offending medications. It is only after failure to improve that
patients undergo kidney biopsy and the diagnosis is confirmed. New direct-acting antiviral agents have generally
been well received as safe and efficacious therapies for hepatitis C virus (HCV) infection; however, physicians
should be vigilant for drug-induced kidney injury at all times, especially when using newer agents because adverse
effects may not be known yet.
CASE REPORT
A 66-year-old white man with Child-Pugh A cirrhosis secondary to HCV genotype 3 on a background of atrial fibril-
lation (AF), hypertension, and gout was found to have an acute kidney injury during treatment. For several years,
his gout had been stable on allopurinol, perindopril, and atenolol with reasonable blood pressure control and rate-
controlled AF. His weight was 89.6 kg, and his serum creatinine ranged from 50 mmol/L to 63 mmol/L during the
past few years. There was no significant family or social history.
His liver fibroscan demonstrated median stiffness (66.4 kpa) consistent with cirrhosis. In light of the HCV genotype
3 infection treatment naivety and compensation, he was started on sofosbuvir-daclatasvir for a total of 24 weeks.
His viral load was <12 IU/mL at his 4-week review, and he was tolerating his medications well, troubled only by fa-
tigue that was thought to be related to his disease.
At week 22 of treatment, his creatinine rose to 91 mmol/L, with complaints of worsened fatigue but no evidence
of liver decompensation on examination. Treatment was continued for its full course of 24 weeks. A repeat
test requested 2 weeks prior to his sustained virological response at 12 weeks (SVR12) showed a creatinine of
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284 mmol/L. On his SVR12 visit, his creatinine had risen to
377 mmol/L and he was immediately admitted to hospital for
further evaluation.
On admission, he complained of generalized joint pain, ano-
rexia, and persistent fatigue. He denied eye or infective
symptoms. Medication review revealed no drug use other
than previously described, and he denied using nonsteroidal
anti-inflammatory agents, antibiotics, and over-the-counter
medications or supplements. Physical examination revealed
blood pressure 150/70 mm Hg and an asymptomatic diffuse
maculopapular rash over the central face extending over the
malar region, nose, and forehead. The remainder of his exami-
nation was unremarkable. Relevant laboratory investigations
demonstrated mild compensated anion-gap acidosis, hemo-
globin 116 g/L, mean corpuscular volume 92 fL, and creatinine
382 mmol/L. Inflammatory markers including C-reactive pro-
tein and white cell count were not elevated. Urine analysis
showed 10–40 leukocytes/high power field, >100 erythro-
cytes/high power field, and proteinuria ranging from ne-
phrotic to non-nephrotic with no growth on repeated
cultures. The leukocyte count was too low to perform an
accurate eosinophil count. There was no gross hematuria,
complement C3 and C4 levels were normal, and autoimmune
screens (Rh factor, antinuclear antibody, anti–double-
stranded DNA antibodies, anti-neutrophil cytoplasmic anti-
bodies, extractable nuclear antigens) were all negative.
Allopurinol and perindopril were discontinued, and no
improvement was seen with intravenous hydration. The
patient remained vitally stable with normal urine output. A re-
nal ultrasound showed normal kidneys with a mild diffuse
increase in echogenicity. A kidney biopsy showed extensive
tubulointerstitial nephritis with eosinophils (Figure 1). Other
features included background mesangioproliferative immu-
noglobulin (Ig) A nephropathy with 1 crescent and no evi-
dence of acute tubular necrosis or cryoglobulinemia (Figure
2). Electron microscopy demonstrated mesangial enlarge-
ment and sclerosis consistent with IgA nephropathy. In the
clinical context, the reviewing pathologist and nephrologist
made a diagnosis of drug-induced AIN.
The patient’s creatinine continued to rise, and oral predni-
solone (60 mg/d) was started. His creatinine peaked at
491 mmol/L and then improved, as did the facial rash. Due to
fluid retention side-effects of steroid therapy, he required
dose reduction to 40 mg/d and brief frusemide therapy dur-
ing this period. He continues to be followed up with notable
improvement of his creatinine to 284 mmol/L after weaning
from immunosupression.
DISCUSSION
The most common etiology of AIN is drugs (75% of cases),
however, infections, systemic diseases, and idiopathic causes
can also be responsible. Renal manifestations appear as little
as 1 day after medication use or as much as several months
later with some medications.1 The classic triad of fever, rash,
and eosinophilia occurred together in only a minority of
patients.1 Features such as arthralgias, microhematuria, leuko-
cyturia, and proteinuria are common.1
Our patient did not have physical or laboratory indications
of infection or systemic disease. The temporal relationship
of use of sofosbuvir-daclatasvir, rising creatinine levels,
Figure 1. Kidney biopsy specimen showing intersitial eosinophils (arrows)
at 400xmagnification, typical of drug-induced acute interstitial nephritis.
Figure 2. Immunofluorescence staining of kidney biopsy showing IgA
deposits.
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development of facial maculopapular rash, arthalgias, and an-
orexia are strongly suggestive of sofosbuvir-daclatasvir-
induced AIN. Although our patient had been using allopuri-
nol, which has been known to cause AIN, for >7 years at a
renally adjusted dose of 200 mg daily, his dose was reduced
to 100 mg early upon deterioration and was immediately
stopped on hospital admission. It is unlikely to be responsible
for his acute presentation.
Biopsy findings of elements characteristic of AIN were key to
the diagnosis. The additional features of IgA nephropathy are
not uncommon in cirrhotic individuals, and the strong associa-
tion is well known, in particular when secondary to HCV.2-5
Despite high frequency, most patients are apparently healthy
individuals with no clinical signs of glomerular disease.5-7
Only one case of biopsy-proven AIN associated with direct-
acting anti-virals ledipasvir-sofosbuvir exists in the literature.8
Another published example involves the concomitant use of
ledipasvir-sofosbuvir and tenofovir in a patient with HCV and
human immunodeficiency virus coinfection.9 The authors
postulated that the kidney injury was secondary to the known
interaction between ledipasvir and tenofovir disoproxil fuma-
rate, resulting in increased tenofovir exposure. It was thought
that tenofovir caused the kidney damage. The kidney biopsy
showed evidence of both acute tubular necrosis and AIN with
a relatively clear temporal relationship. The common sofosbu-
vir link in all 3 cases suggests that the AIN component was in
fact related to sofosbuvir. We found no published reports of
kidney injury related to daclatasvir and therefore believe
sofosbuvir is the most likely culprit in our patient’s AIN.
From our review of the literature, this is the first biopsy-pro-
ven case where use of sofosbuvir and daclatasvir for treat-
ment of HCV genotype 3 was associated with AIN. Physicians
should be vigilant for drug-induced kidney injury at all times,
especially when using newer agents because the full range of
effects may not be known.
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